Current and emerging treatment strategies for breast cancer-induced bone loss

Figures & data

Table 1 Bisphosphonates in postmenopausal women

Authors	Year	Cancer therapy	Bisphosphonates	Dose	Time interval	Lumbar spine BMD % change (% change placebo)	Difference (%)	Other BMD	BMD % change (% change placebo)	Difference (%)
Delmas^Citation27	1997	Chemotherapy ± tamoxifen	Risedronate	30 mg daily × 14 d q12wk	1 y	0.3 (−1.4%)	+ 1.7	Trochanter	0.6 (−0.8%)	+ 1.4
Greenspan^Citation26	2007	Chemotherapy ± tamoxifen or AI	Risedronate	35 mg weekly	1 y	1.2 (−0.9%)	+2.1	Hip	1.3 (−0.8%)	+2.1
Brufsky^Citation22	2007	Letrozole	Zoledronic acid	4 mg IV q6 mo	1 y	1.9 (−2.4%)	+4.4	Total hip	1.3 (−1.98%)	+3.3
Lester^Citation24	2008	Anastrozole	Ibandronate	150 mg monthly	2 y	2.98 (3.22%)	+6.2	Total hip	0.60 (−3.90%)	+4.5
Hines^Citation23	2009	Letrozole	Zoledronic acid	4 mg IV q6 mo	1 y	3.66 (−1.66%)	+5.32	Femoral neck	2.08 (−0.09%)	+2.17
van Poznak^Citation25	2010	Anastrozole	Risedronate	35 mg weekly	2 y	2.2 (−1.8%)	+4.0	Total hip	1.8 (−1.1%)	+2.9

Abbreviation: BMD, bone mineral density.

Table 2 Bisphosphonates in postmenopausal women with osteoporosis or significant osteopenia (T score ≤2.0)

Authors	Year	Cancer therapy	Bisphosphonates	Dose	Time interval	Lumbar spine BMD % change	Other BMD	BMD % change
Lester^Citation24	2008	Anastrozole	Ibandronate	150 mg monthly	2 y	+3.52	Total hip	+2.49
Hines^Citation23	2009	Letrozole	Zoledronic acid	4 mg iv 96 mo	1 y	+2.66	Femoral neck	+4.81
van Poznak^Citation25	2010	Anastrozole	Risedronate	35 mg weekly	2 y	+3.0	Total hip	+2.0

Abbreviation: BMD, bone mineral density.

Table 3 Bisphosphonates in premenopausal women

Authors	Years	Cancer therapy	Bisphosphonates	Dose	Time interval	Lumbar spine BMD % change (% change placebo)	Difference (%)	Other BMD	BMD % change (% change placebo)	Difference (%)
Saarto^Citation30	1997	Chemotherapy (CMF × 6)	Clodronate	1,600 mg daily	2 y	−2.2 (−5.9%)	+3.7	Femoral neck	0.9% (−2.0%)	+2.9
Powles^Citation3	1998	Chemotherapy ± tamoxifen	Clodronate	1,600 mg daily	2 y	−0.16 (−1.88%)	+ 1.72	Total hip	1.13% (−0.72%)	+ 1.85
Hines^Citation25	2009	Chemotherapy ± tamoxifen	Risedronate	35 mg weekly	1 y	−4.3 (−5.4%)	+ 1.1	Femoral neck	−2.2% (−2.4%)	+0.2

Abbreviations: CMF, cyclophosphamide methotrexate fluorouracil; BMD, bone mineral density.

DelmasPDBalenaRConfravreuxEHardouinCHardyPBremondABisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled studyJ Clin Oncol19971539559629060533

 PubMed Web of Science ®Google Scholar

GreenspanSLBhattacharyaRKSereikaSMBrufskyAVogelVGPrevetnion of bone loss in survivors of breast cancer: a randomized double-blind, placebo-controlled clinical trialJ Clin Endocrinol Metab20079213113617047022

 PubMed Web of Science ®Google Scholar

BrufskyAHarkerWGBeckJTZoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancerJ Clin Oncol200725782983617159193

 PubMed Web of Science ®Google Scholar

LesterJEDodwellDPurohitOPPrevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancerClin Cancer Res200814196336634218829518

 PubMed Web of Science ®Google Scholar

HinesSLMinceyBDentchevTImmediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CCBreast Cancer Res Treat200911760360919214743

 PubMed Web of Science ®Google Scholar

van PoznakCHannonRAMackeyJRPrevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trialJ Clin Oncol201028696797520065185

 PubMed Web of Science ®Google Scholar

SaartoTBlomqvistCVälimäkiMPäkeläPSarnaSElomaaIChemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsJ Clin Oncol1997154134113479193325

 PubMed Web of Science ®Google Scholar

ShapiroCLManolaJLeboffMOvarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancerJ Clin Oncol200119143306331111454877

 PubMed Web of Science ®Google Scholar